Detalhe da pesquisa
1.
Resident Macrophages: Near and Dear to Your Heart.
Cell
; 169(3): 376-377, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28431239
2.
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αß+ T cells targeting multiple myeloma.
Blood
; 143(10): 895-911, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890146
3.
ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma.
Blood
; 143(11): 996-1005, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992230
4.
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551812
5.
Single-cell profiling in multiple myeloma: insights, problems, and promises.
Blood
; 142(4): 313-324, 2023 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37196627
6.
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
Blood
; 141(13): 1574-1583, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984902
7.
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Blood
; 141(6): 620-633, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223594
8.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Blood
; 141(21): 2599-2614, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630605
9.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603186
10.
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Blood
; 141(23): 2841-2852, 2023 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877894
11.
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Blood
; 141(4): 391-405, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126301
12.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 384(8): 705-716, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626253
13.
Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.
Gastroenterology
; 165(2): 357-373, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37178737
14.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
15.
Role of minimal residual disease assessment in multiple myeloma.
Haematologica
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328864
16.
DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification.
Haematologica
; 109(1): 231-244, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439377
17.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
18.
Risk factors in multiple myeloma: is it time for a revision?
Blood
; 137(1): 16-19, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024991
19.
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Blood
; 138(20): 1980-1985, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792571
20.
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Blood
; 138(20): 1966-1979, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132782